The World Marrow Donor Association has formulated guidelines for establishing the extent and quality of histocompatibility testing for unrelated donor registries, umbilical cord blood banks, and transplant centers involved in international exchange of hematopoietic stem cells for allogeneic transplantation. The ability to identify unrelated stem cell donors in one country for patients in another country requires cooperation and standardization in many areas. The adoption of guidelines for histocompatibility testing, such as those summarized in this report, will facilitate these opportunities and rapidly provide accurately typed donors for patients in need.
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1,2 The goal of this document is to outline general guidelines that might be used to establish the extent and quality of histocompatibility testing for unrelated donor registries, umbilical cord blood banks, and (1) Registries (and banks) must respond to search requests and to requests for additional information and/or an aliquot of donor sample (ie blood or DNA required for additional histocompatibility testing) in a timely and defined fashion. (2) Donors (or cord blood units) selected for a specific patient must be placed on a 'not available' status until the transplantation date is reached. A maximum time limit for this status should be set in writing.
II Umbilical Cord Blood Banks
A The same guidelines as recommended for adult donor registries should be followed.
III Transplant center's laboratory for patient, family and selected donor typing
A HLA loci and individuals to test
(1) HLA-A,-B,-DR must be tested. Typing for other HLA loci including HLA-C, HLA-DRB3, -DRB4, -DRB5 and -DQB1 is highly recommended. (2) Typing of siblings and parents of the patient should be used, whenever possible, to identify any sibling donors, to confirm the patient's HLA types, and to define haplotypes. An extended family typing might be undertaken to identify a related donor. (2) Prior to transplant, typing of patient and donor must be repeated on fresh samples using an optimal set of reagents and methodology. Both patient and donor should be typed with the same set of reagents, methodology, and interpretation criteria, preferably in the same laboratory.
F Time limits on testing
(1) For those patients for whom transplantation is an appropriate therapy, family typings and preliminary unrelated searches should be performed early to facilitate consideration of treatment options.
